|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肝移植临床免疫抑制剂及新药研究进展显示文摘肝移植临床常用的免疫抑制剂主要包括钙调磷酸酶抑制剂类药物,如环孢素(CsA)和他克莫司(FK506)等;糖皮质激素类药物,如泼尼松和泼尼松龙等;细胞毒类药物,如硫唑嘌呤、吗替麦考酚酯及环磷酰胺等;哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂类药物,如西罗莫司和依维莫司;抗体类药物如多克隆抗体、单克隆抗体及白细胞介素(IL)-2受体抗体等。免疫抑制剂虽然种类繁多,但目前大多数肝移植受者主要使用FK506。然而,FK506在肝移植后期表现出明显的不良反应,尤其是引起严重感染和肾毒性。因此,研发免疫耐受作用强和不良反应小的新型免疫抑制剂成为临床上迫切需要解决的难题和研究热点。本文就目前肝移植免疫抑制剂的研究进展和新型免疫抑制剂的研发状况进行综述。 | 陈泉余 蒋师放 夏仁培 帅领 张宏宇 白莲花 | 2020 | 器官移植2020，11，6： | 8 |
| 2 | CD4+T cells memorize obesity and promote weight regain显示文摘Body weight regain often causes failure of obesity therapies while the underlying mechanism remains largely unknown.In this study,we report that immune cells,especially CD4+T cells,mediate the‘memory’of previous obese status.In a weight gain-loss-regain model,we found that C57BL/6J mice with an obesity history showed a much faster rate of body weight regain.This obesity memory could last for at least 2 months after previously obese mice were kept at the same body weight as non-obese mice.Surprisingly,such obesity memory was abrogated by dexamethasone treatment,whereas immunodeficient Rag1−/−and H2A−/−mice failed to establish such memory.Rag1−/−mice repossessed the obesity memory when immune cells or CD4+T cells isolated from previously obese mice were transferred.Furthermore,depletion of CD4+T cells led to obesity memory ablation.Taken together,we conclude that CD4+T cells mediate obesity memory and promote weight regain. | Jianghuan Zou Beibei Lai Mingzhu Zheng Qin Chen Shujun Jiang Anying Song Zan Huang Peiliang Shi Xin Tu Di Wang Linrong Lu Zhaoyu Lin Xiang Gao | 2018 | Cellular & Molecular Immunology2018，15，6： | 2 |
| 3 | Effects of Histotripsy on Local Tumor Progression in an in vivo Orthotopic Rodent Liver Tumor Model显示文摘Objective and Impact Statement.This is the first longitudinal study investigating the effects of histotripsy on local tumor progression in an in vivo orthotopic,immunocompetent rat hepatocellular carcinoma(HCC)model.Introduction.Histotripsy is the first noninvasive,nonionizing,nonthermal,mechanical ablation technique using ultrasound to generate acoustic cavitation to liquefy the target tissue into acellular debris with millimeter accuracy.Previously,histotripsy has demonstrated in vivo ablation of noncancerous liver tissue.Methods.N1-S1 HCC tumors were generated in the livers of immunocompetent rats(n=6,control;n=15,treatment).Real-time ultrasound-guided histotripsy was applied to ablate either 100%tumor volume+up to 2 mm margin(n=9,complete treatment)or 50-75%tumor volume(n=6,partial treatment)by delivering 1-2 cycle histotripsy pulses at 100 Hz PRF(pulse repetition frequency)with p−≥30 MPa using a custom 1 MHz transducer.Rats were monitored weekly using MRI(magnetic resonance imaging)for 3 months or until tumors reached~25 mm.Results.MRI revealed effective post-histotripsy reduction of tumor burden with near-complete resorption of the ablated tumor in 14/15(93.3%)treated rats.Histopathology showed<5 mm shrunken,non-tumoral,fibrous tissue at the treatment site at 3 months.Rats with increased tumor burden(3/6 control and 1 partial treatment)were euthanized early by 2-4 weeks.In 3 other controls,histology revealed fibrous tissue at original tumor site at 3 months.There was no evidence of histotripsy-induced off-target tissue injury.Conclusion.Complete and partial histotripsy ablation resulted in effective tumor removal for 14/15 rats,with no evidence of local tumor progression or recurrence. | Tejaswi Worlikar Mishal Mendiratta-Lala Eli Vlaisavljevich Ryan Hubbard Jiaqi Shi Timothy L.Hall Clifford S.Cho Fred T.Lee Joan Greve Zhen Xu | 2020 | Biomedical Engineering Frontiers2020，1，1： | 1 |
| 4 | 间充质干细胞与黑素细胞共培养的研究进展显示文摘自体黑素细胞移植为稳定期白癜风的一线治疗手段。该治疗虽已被证实复色有效,但是如何维持移植细胞的未分化状态、提高移植细胞的活力、增加其在移植区的附着度,最大程度实现复色目的尚需进一步研究。既往研究多局限于单纯黑素细胞或黑素细胞与角质形成细胞共培养,但获得足够数目的自体角质形成细胞会遗留大面积瘢痕。间充质干细胞是目前临床研究的理想种子细胞,来源丰富、获取方便,与黑素细胞共培养有望促进移植区复色。本文对间充质干细胞与黑素细胞共培养的研究进展做一综述。 | 滕佳男 王红娟 康晓静 | 2022 | 中国皮肤性病学杂志2022，36，9： | 0 |
| 5 | 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展显示文摘异基因造血干细胞移植(allo-HSCT)是治愈血液系统疾病的一种有效方法。血小板减少是allo-HSCT后常见且严重的并发症,与预后不良相关。成分血输注、促进血小板生成及释放药物、糖皮质激素等可用于allo-HSCT后血小板减少的治疗,但疗效有限。近年来,随着对allo-HSCT后血小板减少发病机制的研究,间充质干细胞(MSCs)及血小板生成素受体激动剂(TPO-RA)已作为其治疗选择,且证明安全有效。本文就MSCs联合TPO-RA在allo-HSCT后血小板恢复中的作用机制及安全性和有效性进行综述。 | 刘文慧 吴涛 张曦 | 2023 | 中华细胞与干细胞杂志(电子版)2023，13，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员